TRANS GENIC GROUP INC.JP:2342Income statement

Market cap
¥4.8B
P/E ratio
117.1x
Transgenics Group supports drug development through specialized lab services like genetically modified mice production and pharmaceutical testing, while also providing business consulting and importing various products from electrical equipment to tableware.
2012/032013/032014/032015/032016/032017/032018/032019/032020/032021/032022/032023/032024/032025/03
Revenue6087041,6181,9592,2902,3033,6018,67511,04711,04612,57711,43013,08313,005
Revenue growth (%)--
Cost of revenue---1,3021,6181,5542,7797,1769,2678,2698,7419,43510,83410,838
Gross profit---6576737498221,4981,7802,7773,8361,9952,2492,167
Gross margin (%)---
Operating margin (%)---
Operating expenses ---6336225957621,2281,6061,8841,9992,0202,1602,426
Operating income ---2450154612701748931,837-2589-260
Income before tax -120-32-1229198814256958921,819199108-320
Pretax margin (%)-19.8-4.5-7.60.50.83.80.430.98.114.51.70.8-2.5
Provision for income taxes----341-6119115390810839415
Effective tax rate (%)---
Net income -16219-10218158121202-4415461,876-4104-1,090
Net income margin (%)
Earnings per share-12.062.09-8.391.291.055.631.4111.95-25.3831.45109.52-24.320.24-65.51
Diluted EPS-2.08-1.291.055.621.3911.91-31.45109.31---
Dividend payout ratio (%)------------
Dividend per share---------3653-
EBITDA---
EBITDA margin (%)---